Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Zenocutuzumab Granted FDA Orphan Drug Designation in Cholangiocarcinoma

Summary by oncnursingnews.com
Patients with NRG1 fusion-positive cholangiocarcinoma who received zenocutuzumab had a favorable response rate in the phase 1/2 eNRGy trial.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

oncnursingnews.comoncnursingnews.com

Zenocutuzumab Granted FDA Orphan Drug Designation in Cholangiocarcinoma

Patients with NRG1 fusion-positive cholangiocarcinoma who received zenocutuzumab had a favorable response rate in the phase 1/2 eNRGy trial.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

oncnursingnews.com broke the news in on Thursday, February 12, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States icon

United States

Cholangiocarcinoma icon

Cholangiocarcinoma

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal